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Introduction
There is a significant heritable component of prostate cancer. Increased familial relative risk is observed across multiple populations. Male first degree relatives of prostate cancer patients have a two-to three-fold increased risk. Segregation analyses support genetic rather than shared environmental risk. Twin cancer concordance studies reveal a higher heritable risk for prostate cancer than for any other common cancer. Additional epidemiological studies have been consistent with X-linked transmission, identifying higher risk for a man with an affected brother relative to one with an affected father. Despite the overwhelming genetic predisposition evidence, the identification of prostate cancer susceptibility genes has been difficult. Linkage studies have resulted in the identification of several loci difficult to confirm across study populations. However, summary studies of genome-wide scans for prostate cancer susceptibility loci in general confirm two loci, HPC-1 and HPC-X.
Our study seeks to identify a candidate gene or genes conferring prostate cancer susceptibility at locus HPC-X in a US Caucasian study population. We hypothesize that a gene or genes at HPC-X harbor common moderate-penetrance variants predisposing to prostate cancer. We looked at shared haplotypes in founder populations and found two intervals likely to harbor prostate cancer susceptibility genes. We have chosen to first focus on one interval at locus HPC-X (termed HPC-X region A) due to shared haplotype association evidence in the founder populations of Finland, Iceland and Ashkenazim.
Body Accomplishments
Results from Tasks Perform de novo SNP discovery at predicted or known genes and derive a set of survey SNPs spanning the HPC-X locus and a density of 3-5 kb from dbSNP b.
Genotype a subset of the study population for all SNPs in 1a c.
Analyze genotypes to determine genetic architecture of HPC-X Task 1a-1c has been completed.
To derive a set of survey SNPs spanning the interval at HPC-X we assayed SNPs found in dbSNP for polymorphism in a subset of 40 prostate cancer cases from the training dataset. Out of 415 SNPs culled from database entries, we identified 194 as polymorphic and assayable in our study population. To augment this set of SNPs, we undertook de novo SNP discovery in the same subset of 40 prostate cancer cases at 2 known and predicted genes in the region, identified in Figure 1 . In addition to known genes SPANXC and LDOC1, custom software identified a coding region containing homology to RPL44 and a pseudogene containing homology to RBMX2. De novo SNP discovery at these four features resulted in 52 additional SNPs for a total of 246 SNPs. Linkage disequilibrium (LD) patterns at HPC-X Region A for these 246 SNPs typed in a subset of 141 controls of our training population are presented in Figure 1 . Four major blocks of LD are apparent. Block "A" contains all four known and predicted genes.
Task 2. To determine a set of tagging SNPs across our candidate interval at HPC-X, to genotype them in the training dataset and to test for significant association with risk of prostate cancer a. Determine a set of tagging SNPs across our candidate interval at HPC-X from the 246 SNPs typed in Task 1 b.
Genotype tagging SNPs in the remainder of the training dataset population c.
Using single allele and sliding window haplotype analysis, determine haplotype windows statistically associated with risk of prostate cancer
Task 2 a-c has been completed. 
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Using LDSelect, we have determined a set of 128 tagging SNPs (r 2 > 0.9) and typed them in the remainder of our training dataset (N = 292 cases, 292 age-matched controls). All windows of statistical significance conferring risk of prostate cancer (nominal P ≤ 0.05) within the candidate interval were from four distinct regions and are seen in Table 2 of the attached manuscript. Regions are listed from 5' to 3' across the candidate interval. Individual SNPs in each haplotype are identified with an internal seven-digit code. Case and control frequencies are seen for the haplotype window with the most significant P value, colored in black. All other haplotype windows showing statistical significance are colored in grey.
Task 3. To confirm associated prostate cancer gene variants in a second study population, and to extend investigation in an African American Study population. (Months 24-36) a.
Ascertainment of independent population to be used as a test dataset b.
Confirm or refute areas of statistical association from Task 2 in test dataset c.
Extend findings into an African American study population, currently under ascertainment Task 3 a, b has been completed. Task 3c is in progress.
We have recently ascertained an independent test dataset of 215 prostate cancer probands with a family history of disease and 215 age-matched controls. We used this dataset to confirm or refute statistical associations seen in the training dataset. We identified haplotype tagging SNPs (htSNP) for each of the four candidate risk haplotypes encompassing the entirety of each associated region and tested for association with risk of prostate cancer in our test dataset (Table 3 in the attached manuscript). Case and control frequencies differ from those reported in Table 2 due to the use of only htSNPs to define the haplotype, allowing inclusion of some samples previously dropped from analysis due to missing data. Haplotype 3 was statistically significant within the test population (6.6% of cases, 2.5% of controls; P = 0.04). This haplotype spans areas "A" and "B" as seen in Figure 1 , identifying a recombination hotspot. Using permutation testing, this result was still significant after adjustment for multiple testing (P = 0.048).
We currently do not have sufficient power in our African American dataset and as a result, we are actively increasing our ascertainment efforts.
Conclusions
Over the past two years, we have been systematically dissecting HPC-X to uncover the variant or variants responsible for its association with risk of prostate cancer. Starting with region A, whose boundaries we identified through shared haplotype analysis of founder populations, we have identified one haplotype tagged by 6 htSNP spanning a 22.8 kb region pinpointing a recombination hotspot associated with risk of prostate cancer. This haplotype was statistically significant for risk of prostate cancer in both our test and training datasets.
ORIGINAL INVESTIGATION
A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer Abstract We conducted an association study to identify risk variants for familial prostate cancer within the HPCX locus at Xq27 among Americans of Northern European descent. We investigated a total of 507 familial prostate cancer probands and 507 age-matched controls without a personal or family history of prostate cancer. The study population was subdivided into a set of training subjects to explore genetic variation of the locus potentially impacting risk of prostate cancer, and an independent set of test subjects to conWrm the association and to assign signiWcance, addressing multiple comparisons. We identiWed a 22.9 kb haplotype nominally associated with prostate cancer among training subjects (292 cases, 292 controls; 2 = 5.08, P = 0.020), that was conWrmed among test subjects (215 cases, 215 controls; 2 = 3.73, P = 0.040). The haplotype predisposed to prostate cancer with an odds ratio of 3.41 (95% CI 1.04-11.17, P = 0.034) among test subjects. The haplotype extending from rs5907859 to rs1493189 is concordant with a prior study of the region within the Finnish founder population, and warrants further independent investigation.
Background
Linkage and genetic epidemiological data support the existence of genetic variants on the X chromosome that predispose to prostate cancer (Woolf 1960) . Prostate cancer loci on both arms of the X chromosome have been identiWed, including the HPCX locus at Xq27-28 (Bochum et al. 2002; Brown et al. 2004; Chang et al. 2005; Cunningham et al. 2003; Farnham et al. 2005; Gillanders et al. 2004; Gudmundsson et al. 2008; Lange et al. 1999; Schleutker et al. 2000; Xu et al. 1998) . The »14 Mb linkage interval of HPCX was originally delineated within US, Swedish, and Finnish hereditary prostate cancer pedigrees (Xu et al. 1998) . Further shared haplotype analysis among Finnish probands reWned the locus to a candidate interval Xanked on either side by a notable 113 kb inverted repeat (BaVoeBonnie et al. 2005a, b) . The 352 kb area between these inverted repeats was the candidate interval for the present study ( Fig. 1) , which sought evidence of association with familial prostate cancer among Americans of Northern European descent. Our study population was uniquely comprised of independent familial prostate cancer probands, matched to controls with no personal or family history of prostate cancer. These two groups represent extremes of potential genetic load for prostate cancer. Our study included a training set of 292 case-control pairs to identify nominal associations, and a test set of 215 case-control pairs to conWrm or to refute observations within the training set. We conducted extensive allele discovery and validation within the study population, characterized linkage disequilibrium (LD) patterns, and selected tagging SNPs for tests of association by haplotype-based methods. Our investigation comprehensively tested association of the candidate interval with prostate cancer, and included non-unique genomic regions that are not amenable to current highthroughput techniques.
Materials and methods
Samples
Study subjects were Americans of Northern European descent, ascertained with informed consent between 2002 and 2007 from Vanderbilt University Medical Center and from the VA Tennessee Valley Healthcare System (adjacent hospitals) with institutional review board oversight. Subjects were residents of Tennessee (75%), Kentucky 3 MB of Xq27.1-27.3 depicting previously genotyped STR markers, annotated genes, and a complex HPCX speciWc repeat is shown at top (red bounding box, NCBI build 36.1 ChrX: 139005624-142009903 bp). The candidate interval for study is zoomed at bottom (blue bounding box, ChrX:140046709-140391709 bp). The interval contains SPANXC and LDOC1, as well as a predicted RPL44 homolog and a pseudogene of RBMX2. As members of larger gene families, unique long-range amplimers (denoted) were required to ensure site-speciWc assays. Polymorphic SNPs (N = 246) are positioned on the map (tagging SNPs in pink). At bottom is a pairwise LD matrix for 141 controls across the subset of 220 SNPs with MAF¸0.05. Red DЈ = 1 (lod ¸2); blue DЈ = 1 (lod <2); pink DЈ < 1 (lod¸2); white DЈ < 1 (lod <2). Blocks of LD are denoted A, B, C and D. Block A contains all four candidate gene regions (15%), Georgia (2%), Alabama (1%), Mississippi (1%), Virginia (1%), and other states (4%). Familial prostate cancer cases were ascertained at the time of treatment for the principal diagnosis of prostate cancer, and controls were ascertained at the time of routine preventative screening for prostate cancer. All prostate cancer probands included in the study are from pedigrees with a family history of prostate cancer, and all control probands are from pedigrees without a family history of prostate cancer. Family history included Wrst and second degree relatives. Controls had a screening prostate speciWc antigen (PSA) test <4 ng/ml at the time of ascertainment, and had no record of a PSA tesţ 4 ng/ml or record of abnormal digital rectal examination. Controls were matched to cases on age ( §2.5 years; age at screen for controls, age at diagnosis for cases). Case and control pedigrees were of comparable size. The mean number of at-risk male siblings was 1.7 for cases, and 1.8 for controls. Initial accruals included 292 unrelated, independent familial prostate cancer probands and 292 agematched controls, comprising a training study group. Subsequent accruals included 215 additional unrelated, independent prostate cancer probands and 215 additional agematched controls, comprising a separate test study group. The geographical distribution (by state of residence) of training and test subjects was not signiWcantly diVerent. Analyses preferentially employed prostatectomy specimen over biopsy Gleason score (available for 87% of cases). Table 1 provides characteristics of the study population.
Genotyping methods DNA was extracted from whole blood using the Puregene DNA PuriWcation System Standard Protocol (Qiagen, Valencia, CA). DNA was quantiWed using the PicoGreen dsDNA Quantitation Kit (Invitrogen, Carlsbad, CA), imaged with a Molecular Devices/LJL Analyst HT (Molecular Devices, Union City, CA). We genotyped SNPs by single nucleotide primer extension and Xuorescence polarization, as previously described (Yaspan et al. 2007 ). Both forward and reverse strand extension primers were tested to select the most robust assay. Amplimer and extension primer sequences for tagging SNPs are provided in Electronic supplementary Table 1 .
Candidate polymorphisms
To capture genetic diversity across the candidate interval, database SNPs annotated in dbSNP were screened for common polymorphism in a set of 40 independent familial prostate cancer probands from the training study group. This included 415 annotated SNPs on chromosome X between positions 140,036,557 and 140,388,361 (NCBI Build 36.1). The screening set was estimated to provide 98% power to detect a polymorphism with a minor variant frequency of 0.10, and 87% power with a frequency of 0.05. These 40 prostate cancer cases were also used for de novo SNP discovery at known and predicted genes within the candidate interval: 4.6 kb 5Ј to 0.2 kb 3Ј of LDOC1; 1.6 kb 5Ј to 4.4 kb 3Ј of SPANXC; 3.0 kb 5Ј to 1.4 kb 3Ј of a predicted coding region containing homology to ribosomal protein L44 ("hRPL44"); and 2.3 kb 5Ј to 0.8 kb 3Ј of a predicted pseudogene containing homology to RBMX2 ("RBMX2P1"). The latter two annotations were identiWed by aligning transcript evidence on the genomic map. We employed two single-stranded conformation polymorphism methods (redundant) and re-sequencing for SNP discovery, as previously described (Yaspan et al. 2007 ). Exons of the four genes were also re-sequenced for all 40 prostate cancer cases in the screening set.
Nested ampliWcation of non-unique regions
Non-unique regions of SPANXC, hRPL44 and RBMX2P1 were assayed using a nested reaction strategy. Unique priming sites were identiWed Xanking non-unique regions and ampliWed using the Expand Long Template PCR System Table 1 . Long-range PCR product was then diluted 1:5,000,000 to dilute carry-over genomic template to nonampliWable levels while retaining the ability to amplify from the long-range PCR product. This was veriWed by successful test of amplimers nested within the template longrange PCR product, but failure of amplimers elsewhere in the genome. Nested amplimers were designed in overlapping fashion along a given long range amplimer, enabling PCR-based assays. These primers are provided in Electronic supplementary Table 2 . High pairwise LD between SNPs within a given non-unique region and Xanking unique SNPs supported correct non-unique copy assay (visible in Fig.1 ). All nested assays within long-range amplimers yielded one allele per subject, concordant with a unique X-chromosomal region for a male.
Tag SNP determination
Tagging SNP determination was conducted in a subset of 141 training set control subjects that were genotyped at 246 SNPs (including 194 validated from dbSNP and 52 identiWed by de novo discovery eVorts). Pairwise LD was visualized using Haploview v4 (Barrett et al. 2005) . LDSelect was used for tagging SNP selection, specifying a MAF threshold of 0.05 and an r 2 threshold of 0.9 (Carlson et al. 2004) . A total of 128 tagging SNPs were selected for assay in the remaining subjects of the training set (totaling 292 independent familial case probands and their 292 agematched controls). Data were obtained for 96.2% of the 74,752 tagging genotypes sought in the training subjects, with a per marker range from 88.4 to 100%. SNPs in this tagging set and their assay primers are listed in Electronic supplementary Table 1 .
Statistical analyses
A sliding window approach tested a haplotype window of N markers, sliding the window along the map in single marker increments (Fallin et al. 2001; Mathias et al. 2006; Yaspan et al. 2007) . Each N-marker haplotype was compared to the remaining haplotypes as a group among the training group of 292 cases and 292 matched controls. The resulting 2 £ 2 contingency table was evaluated by the 2 test statistic. Haplotype windows of 1-10 markers were evaluated in the exploratory analyses of training subjects. In a given map region that was nominally associated with prostate cancer within the training subjects (P · 0.05), haplotype tagging SNPs (htSNPs) were selected that most eYciently distinguished the risk haplotype from others in the region. Nominally signiWcant tagged haplotypes (two observed) were genotyped in a subsequently ascertained independent test group of 215 cases and their 215 matched controls to address multiple comparisons. SigniWcance for a given tagged haplotype candidate was adjusted for the two comparisons among test subjects through permutation testing. We generated 5,000 copies of the data set in which pseudo case status was permuted among cases and controls of the test group. A 2 value for each tagged haplotype was calculated for each simulated data set, as it was for the real data. Since the null hypothesis is true for each randomized subject set, the proportion of simulated 2 values greater than the real 2 value was used as a P value for the association, adjusted for multiple comparisons. Unless speciWcally noted, P values are unadjusted for multiple comparisons.
A risk haplotype that was signiWcant after adjustment for multiple comparisons among test subjects was subsequently modeled by conditional logistic regression to obtain an estimate of eVect size (Intercooled Stata 9, Stata Corporation, College Station, TX). The regression model was adjusted for the matching variable: age (age at diagnosis for cases, age at negative screen for controls). Permutation testing was employed to assign signiWcance.
Results and discussion
Our allele discovery and characterization was done within a screening set of 40 familial prostate cancer probands from the training group. We evaluated 415 SNPs annotated in dbSNP, 194 of which were polymorphic in these subjects. We also undertook de novo SNP discovery eVorts across LDOC1 and SPANXC, as well as across an RPL44 homolog and RBMX2P1 pseudogene. Among these, only LDOC1 resides within a region of unique genomic sequence. We devised a nested ampliWcation system to allow assay of non-unique genomic sequence Xanked by unique sequence. Collectively, we discovered 52 common SNPs amenable to assay. The 246 polymorphic SNPs (194 from dbSNP, 52 newly discovered) of the screening subjects were genotyped in a subset of the training study population (141 cases and 141 controls) for assessment of allele frequency and for tagging SNP selection based upon LD patterns. Within this data, 220 SNPs had a minor allele frequency ¸0.05 for inclusion in subsequent analyses. Pairwise LD across the candidate interval for these SNPs highlights four LD blocks (denoted A, B, C, and D in Fig. 1) .
Among the 220 informative SNPs, we selected 128 tagging SNPs for genotyping in the full group of training subjects (292 familial case probands and 292 age-matched controls). We explored evidence of association with prostate cancer using a haplotype-based sliding window approach. This entailed evaluation of 1,235 haplotype windows across the candidate interval. All haplotype windows of statistical signiWcance were from four distinct regions.
At each of the four regions, multiple overlapping windows were consistent with the redundant identiWcation of one haplotype associated with prostate cancer risk. These four candidate risk haplotypes are numbered 1-4 in Table 2 .
Only a subset of SNPs in each of the four regions was required to distinguish the candidate risk haplotype from remaining haplotypes. We identiWed haplotype-tagging SNPs (htSNPs) eYciently capturing the four candidate risk haplotypes (full span of windows P · 0.05) of Table 2 . As our analysis required complete data for each subject across the multiple SNPs of the haplotype, the restricted set of htSNPs provided a better estimate of haplotype frequency. Only two of the four haplotypes were nominally signiWcant when assessed by htSNPs among training subjects (Table 3 , haplotype 1 ( 2 = 5.24, P = 0.023) and haplotype 3 ( 2 = 5.08, P = 0.020)). We evaluated evidence Table 2 Sliding window risk haplotypes at Xq27-training subjects a Sliding haplotype windows of P · 0.05, graphically ordered as most (black) to least signiWcant (left to right) b P for haplotype designated in black, with corresponding numbers of cases and controls, and haplotype frequencies (%) of association between these two htSNP haplotypes and prostate cancer in a second, independent study group of 215 familial prostate cancer probands and 215 age-matched controls. These subjects were accrued after the training subjects over the course of the ongoing study. Numerous exploratory tests were conducted among training subjects, but only two tests were conducted among test subjects, a greatly restricted number of comparisons. Only haplotype 3 was signiWcant among test subjects (Table 3 , 2 = 3.73, P = 0.040). Permutation testing was used to correct this value for the two comparisons conducted in test subjects, yielding P = 0.048. Our study identiWes haplotype 3 as the most likely genetic variant of the interval to be associated with familial prostate cancer, with a nominal signiWcance of P = 0.003 in the combined training and test subjects.
Under logistic regression modeling to assess eVect size, haplotype 3 was associated with prostate cancer with an odds ratio of 3.41 (95% CI 1.04-11.17, P = 0.034) among test subjects, and an odds ratio of 2.52 (95% CI 1.25-5.10, P = 0.006) among combined training and test subjects. The number of cases with aggressive prostate cancer among the test subjects was too few to provide a signiWcant estimate of eVect size. However, the 226 cases with aggressive prostate cancer (Gleason score ¸7) among the full study population yielded a more marked odds ratio of 4.06 (95% CI 1.15-14.31, P = 0.021). Gleason score is among the most important criteria in deWning clinically signiWcant disease. Our results are consistent with linkage data at the locus under stratiWcation for clinically signiWcant disease (Chang et al. 2005) .
The location of the haplotype found to be signiWcantly associated with prostate cancer in this study coincides with that described through prior high-density simple tandem repeat mapping within a Finnish study population (BaVoeBonnie et al. 2005a, b) . Among the simple tandem repeats, bG82i1.1 was most signiWcantly associated with prostate cancer in the prior study. The peak associated haplotype was comprised of alleles at bG82i1.1 (centromeric) and bG82i1.0 (telomeric), P = 0.0014. Haplotype 3 of our study directly overlays the recombination hotspot between LD blocks A and B of Fig. 1 . The most centromeric SNP of the associated haplotype (rs5907859) is 4.0 kb downstream from bG82i1.1. The most telomeric SNP of the associated haplotype (rs1493189) is 1.9 kb downstream from bG82i1.0. The same genomic region of interest is highlighted by our present study of Americans of Northern European descent and the prior study of Finns. We further note that among SNPs evaluated in the genome wide association study of prostate cancer recently published by Thomas et al. rs845189 has a Whole Genome Rank of 1,135 out of 527,869 SNPs assessed, with a signiWcance of P = 0.002 (Thomas et al. 2008 ). This SNP resides at the LD break centered within the disease-associated haplotype of our study.
The associated haplotype region does not harbor known genes. All missense variants of potential interest in the entire candidate interval of 352 kb were within SPANXC, 30 kb from the associated haplotype. These missense variants clustered into two LD groups. The Wrst group (all in exon 1) included D17E, A21V, and M24T. The second group (all in exon 2) included P29S, T30S, D32Y, and M42L. Within a group, a male subject had either each Wrst or each second allele as listed. Additional SPANXC missense variants, E23K, V59F and L68V, did not appear to be in these two LD groups. This allele structure in SPANXC is also evident in data of an independent study (Kouprina et al. 2007) . That study also found no evidence to support an association between SPANXC alleles and risk of prostate cancer. The coding regions of hRPL44 and LDOC1 were without missense variants. We denote RBMX2P1 as a pseudogene, having a mutated initiator methionine, multiple frameshift mutations, and an internal Alu insertion. Thus, the missense variants at SPANXC were among the best potential candidates for association with prostate cancer at Xq27.
The haplotype signiWcantly associated with prostate cancer in this study straddles an LD break, potentially detecting a pair of contributing components located within each of the two bounding LD blocks (e.g. a gene and a longrange regulatory element). In a sliding window haplotype analysis, a haplotype overlapping the two blocks would be particularly suited to detect such a combination. We considered the possibility that causal variants are a pair of non-contiguous SNPs within each LD block. We divided haplotype 3 so that those SNPs in LD block A comprised sub-haplotype 3A, and those in block B comprised subhaplotype 3B. Eighteen of the SNPs within block A and only one SNP within block B had an r 2 > 0.8 with the respective sub-haplotypes. A matrix depiction of pairwise Table 3 Tagged risk haplotypes at Xq27 -training and test subjects Numbers of subjects and tagged haplotype frequencies (%) are indicated . Only a subset of the SNPs demonstrating LD with the two sub-haplotypes had been genotyped as tagging SNPs in the training study group to enable an assessment of disease association. These included rs1012777, ss78456788 (T30S), rs12394263, ss78456800, rs5953578, rs845144, rs714076, rs881223, and ss78456818 in LD block A, and rs5907874 in LD block B. With only one exception, 2 tests of association for these block A SNP-block B SNP pair haplotypes were each associated with prostate cancer in our training group (P range 0.0008-0.030). These SNP pairs and the original sliding window haplotype spanning the LD break each detect the association with prostate cancer with varying eYciencies.
Our study sought to identify the genetic variant predisposing to familial prostate cancer at Xq27, a locus initially identiWed by linkage study of American, Swedish, and Finnish hereditary prostate cancer pedigrees, and subsequently reWned by linkage disequilibrium analysis of the Finnish familial prostate cancer cases. After a comprehensive eVort in the present study, we identiWed a single candidate haplotype that was associated with familial prostate cancer within independent training and test study subjects. Although the replication was encouraging, the sample size of our test group was suYciently small that an independent assessment of signiWcance is warranted. Population structure is unlikely to represent a confounding factor within our study, as self-described ethnicity has recently been shown to accurately represent genetic ancestry among Americans of Northern European descent (Hunter et al. 2007; Tang et al. 2005) . We believe that this haplotype represents the best candidate within the region for further investigation within additional study populations. If conWrmed, these Wndings begin to clarify the X-linked heritable component of prostate cancer risk.
